PUBLISHER: The Business Research Company | PRODUCT CODE: 1955348
PUBLISHER: The Business Research Company | PRODUCT CODE: 1955348
Fetal bovine serum (FBS) is a common component of animal cell culture media, used to support the growth of eukaryotic cells cultured in vitro. It is obtained from bovine fetuses harvested from pregnant cows that are about to be slaughtered, typically through cardiac puncture without anesthesia.
The main types of fetal bovine serum include charcoal-stripped, chromatographic, dialyzed, exosome-depleted, stem cell, and others. Charcoal-stripped FBS contains activated carbon, which reduces levels of lipophilic compounds such as hormones, growth factors, and steroids, and is used in receptor or estrogen-related studies. Dialyzed FBS has a lower concentration of small molecules, including nucleotides, amino acids, hormones, salts, and small proteins, making it suitable for cell culture systems requiring a more defined environment. Exosome-depleted FBS removes bovine exosomes present in conventional FBS, facilitating research on exosomes. FBS is applied in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, and other areas. It is used across research and academic institutes, biotechnology and pharmaceutical industries, and other sectors.
Tariffs have impacted the fetal bovine serum market by increasing the cost of imported serum and related lab supplies, disrupting supply chains, and affecting the availability of high-quality products. The impact is most pronounced in Asia-Pacific regions such as China and India, which serve as key suppliers of FBS, as well as in North America and Europe where research and pharmaceutical industries heavily rely on imports. Segments like drug discovery, cell culture media, and vaccine production are particularly affected due to higher costs and delays. However, tariffs have encouraged local sourcing and domestic production initiatives, which could improve supply stability in the long term.
The fetal bovine serum market research report is one of a series of new reports from The Business Research Company that provides fetal bovine serum market statistics, including fetal bovine serum industry global market size, regional shares, competitors with a fetal bovine serum market share, detailed fetal bovine serum market segments, market trends and opportunities, and any further data you may need to thrive in the fetal bovine serum industry. This fetal bovine serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The fetal bovine serum market size has grown strongly in recent years. It will grow from $1.06 billion in 2025 to $1.12 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing use of fbs in cell culture research, growth of biotechnology and pharmaceutical industries, rise in in vitro fertilization procedures, advancements in vaccine production technologies, expansion of academic research institutes.
The fetal bovine serum market size is expected to see strong growth in the next few years. It will grow to $1.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to shift towards serum-free and xeno-free alternatives, rising demand for precision medicine, increasing investments in biotech research, expansion of human and animal vaccine production, adoption of automated cell culture systems. Major trends in the forecast period include enhanced cell culture media formulations, serum-free and alternative media development, quality standardization and regulatory compliance, increasing adoption in vaccine production, expansion in academic and research applications.
The growing demand for dairy and meat products is expected to drive growth in the fetal bovine artificial insemination market. Dairy and meat products, including cheese, yogurt, beef, and pork, are derived from milk processing and livestock. Rising awareness of the nutritional benefits of protein, calcium, and other nutrients has fueled demand for these products. Fetal bovine technologies support this demand by improving herd genetics, enhancing reproductive efficiency, and increasing livestock productivity and quality. For example, in August 2023, the European Commission (EC), the executive branch of the European Union based in Belgium, reported a 0.8% increase in raw milk production in the EU during the first half of 2023. Therefore, the rising demand for dairy and meat products is expected to propel the fetal bovine market.
Key players in the fetal bovine serum market are developing innovative solutions, such as animal-component-free alternatives, to enhance sustainability, address ethical concerns, and support the growing cultivated meat and cell culture industries. Animal-component-free alternatives are serum substitutes that promote cell growth without using animal-derived ingredients. For instance, in December 2024, Multus Biotechnology Limited, a UK-based biotech company, launched Proliferum B for cultivated meat production. This product supports robust cell growth, reduces reliance on animal sources, and accelerates commercialization of sustainable cultured meat. By providing a scalable and ethically sourced solution, Multus aims to overcome cost and supply limitations while promoting sustainable protein production.
In August 2023, URUS Group LP, a US-based company serving dairy and beef cattle producers with genetic solutions, data management, and consulting, acquired Leachman Cattle for an undisclosed amount. This acquisition strengthens URUS's leadership in global cattle genetics by incorporating Leachman's advanced technologies and extensive database to accelerate genetic progress, enhance beef production sustainability, and expand global reach. Leachman Cattle, based in the US, provides high-quality beef genetics through bulls, females, and semen for bovine artificial insemination.
Major companies operating in the fetal bovine serum market are Thermo Fisher Scientific Inc., Merck KGaA, Corning Incorporated, Cytiva, VWR International, Sartorius AG, Bio-Techne Corporation, Atlas Biologicals Inc., R&D Systems Inc., Atlanta Biologicals Inc., Cyagen Biosciences, GenClone Inc., Gemini Bio-Products, Access Biologicals LLC, Nucleus Biologics, ZenBio Inc., Biowest, Bovogen Biologicals Pty Ltd., TCS Biosciences Ltd., J R Scientific Inc., Rocky Mountain Biologicals Inc., Tissue Culture Biologicals, Moregate Biotech, Cell Applications Inc., Altogen Biosystems, Axil Scientific Pte Ltd., Animal Technologies Inc., PAN- Biotech, PAA Laboratories GmbH, Peak Serum Inc.
North America was the largest region in the fetal bovine serum market in 2025. Asia-Pacific recorded the fastest growth during the forecast period. The regions covered in the fetal bovine serum market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the fetal bovine serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fetal bovine serum market consists of sales of Ultra-low IgG, ES Cell, MSC and Exosome-Depleted. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fetal Bovine Serum Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses fetal bovine serum market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for fetal bovine serum ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fetal bovine serum market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.